Hashimoto Masami, Takada Yoko, Takeuchi Yusuke, Kasahara Jiro, Hisa Hiroaki, Shirasaki Yasufumi, Fukunaga Kohji
Department of Pharmacology, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan.
J Pharmacol Sci. 2005 Jun;98(2):142-50. doi: 10.1254/jphs.fp0040551. Epub 2005 Jun 4.
We here assessed the effects of 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e), a novel calmodulin antagonist, on infarct size in the rat heart subjected to ischemia/reperfusion. Rats were subjected to a 30-min coronary occlusion followed by a 24-h reperfusion. DY-9760e was intravenously infused for 20 min, starting at 20 min after coronary occlusion. Treatment with DY-9760e (10 mg/kg) significantly reduced the infarct size in the risk area assessed by Evans Blue/TTC (triphenyltetrazolium chloride) staining. DY-9760e treatment also ameliorated contractile dysfunction of the left ventricle 72 h after reperfusion. DY-9760e significantly inhibited fodrin breakdown and caspase-3 activation. The inhibitory effect of DY-9760e on the fodrin breakdown was prominent in the rim rather than in the center of the risk area. DY-9760e also blocked protein tyrosine nitration associated with infarction. These results suggest that the cardioprotective effect of DY-9760e involved inhibition of calpain/caspase activation and protein tyrosine nitration.
我们在此评估了新型钙调蛋白拮抗剂3-[2-[4-(3-氯-2-甲基苯基)-1-哌嗪基]乙基]-5,6-二甲氧基-1-(4-咪唑基甲基)-1H-吲唑二盐酸盐3.5水合物(DY-9760e)对缺血/再灌注大鼠心脏梗死面积的影响。对大鼠进行30分钟的冠状动脉闭塞,随后进行24小时的再灌注。从冠状动脉闭塞后20分钟开始,静脉输注DY-9760e 20分钟。用DY-9760e(10毫克/千克)治疗可显著减小通过伊文思蓝/TTC(氯化三苯基四氮唑)染色评估的危险区域的梗死面积。DY-9760e治疗还改善了再灌注72小时后左心室的收缩功能障碍。DY-9760e显著抑制血影蛋白降解和半胱天冬酶-3激活。DY-9760e对血影蛋白降解的抑制作用在危险区域的边缘而非中心更为显著。DY-9760e还阻断了与梗死相关的蛋白质酪氨酸硝化。这些结果表明,DY-9760e的心脏保护作用涉及抑制钙蛋白酶/半胱天冬酶激活和蛋白质酪氨酸硝化。